Market For Gene Therapy Is Expected To Surpass US$ 18.72 Billion By 2031

Fact MR Analysis of Gene Therapy provides compelling insights into the factors propelling sales prospects in key segments. It provides an executive-level blueprint of key market players' strategies and analyses their impact on overall growth projections

According to Fact MR's recent market research, Gene Therapy sales will increase at propelled CAGR by 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Gene Therapy will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth potential on the basis of segment.

Request Sample- https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

Key Segments Covered in Gene Therapy Industry Research

Gene Therapy Market by Product :

Yescarta-based Gene Therapy
Kymriah-based Gene Therapy
Luxturna-based Gene Therapy
Strimvelis-based Gene Therapy
Gendicine
Others

Gene Therapy Market by Application :

Ophthalmology
Oncology
Adenosine Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID)

Gene Therapy Market by Region :
North America
Latin America
Europe
East Asia
South Asia
MEA

Request Customization- https://www.factmr.com/connectus/sample?flag=RC&rep_id=4648

Digital Transformation in Healthcare Presenting Opportunities for Gene Therapy Growth

Healthcare organizations around the world are deploying digital tools to accommodating changing consumer preferences. They are pressing on solving the long-standing challenge pertaining to care model innovation.

Considering this, the focus on making healthcare affordable and more transparent will increase. Adoption of care model innovation in healthcare will have a profound impact on the Inflammatory Skin Diseases Treatment Market.

Competitive Landscape

The global gene therapy market is fiercely competitive, with only a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., have a sizable market share in the Gene Therapy market. To secure a position in the global market, various strategic alliances such as collaborations, acquisitions, and the launch of advanced products have been formed.

In October 2021, the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations announced a collaboration to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are expected to boost demand for gene therapy.
BioMarin Pharmaceutical Inc. reported updates on its investigational gene therapy programs in clinical development in February 2022. The Food and Drug Administration (FDA) issued additional requests to the Company for information needed to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021.
Novartis acquired Gyroscope Therapeutics in December 2021, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness.
Abecma (idecabtagene vicleucel), a cell-based gene therapy, was approved by the US Food and Drug Administration in March 2021 to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first FDA-approved cell-based gene therapy for the treatment of multiple myeloma.

Key Gene Therapy Survey Highlights and Projections

Despite COVID-19 outbreak causing enormous strain in the healthcare sector, the Gene Therapy evaluation is expected to total US$ Gene Therapy MN/BN by 2031.
Driven by higher investment in innovation, the U.S. will emerge as the dominant Gene Therapy in North America, accounting for overall sales registered in 2021.
Segment will continue to dominate in terms of segment type, accounting for Gene Therapy sales registered in 2031
With the presence of some of the world's leading healthcare companies, coupled with high spending on hospital services, the U.K. and Germany will emerge as highly lucrative pockets in Europe.
Investment towards healthcare sector expansion and focus on medical tourism will make China, Japan, and South Korea key markets within East Asia.

Buy Now- https://www.factmr.com/checkout/4648

Report Benefits & Key Questions Answered

Gene Therapy Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
Gene Therapy Historical volume analysis: The report provides a comparison of Skincare Serums's historical sales and projected sales performance for 2021-2031.
Gene Therapy manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Inflammatory Skin Diseases Treatment Market. It carefully gauges the impact of changing healthcare needs of key demographics globally
Gene Therapy Consumption by demographics: The report investigates consumer behavior affecting Gene Therapy demand outlook for the assessment period. Effect of their keenness for digital trends on Gene Therapy is carefully analyzed
Post COVID consumer spending on Inflammatory Skin Diseases Treatment Market: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Gene Therapy growth.

For More Insights- https://www.prnewswire.com/news-releases/rising-demand-for-breast-augmentation-to-account-for-nearly-45-of-autologous-fat-grafting-factmr-301273860.html

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Visit Our Website: https://www.factmr.com
Blog URL: https://blog.factmr.com/

About Us:

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.